Qualitative Assessment of Health-Related Quality of Life Impacts Associated with Sickle Cell Disease in the United States and United Kingdom
Individuals with SCD experience negative HRQoL impacts, including impacts to daily activities, social and family life, work and education, psychological health, and prejudice/stigma. Our findings highlight significant unmet needs of individuals living with SCD, including alternative treatment options to reduce vaso-occlusive crisis (VOC) frequency and treat fatigue.
Authors
- Jennifer Drahos (ORCID: https://orcid.org/0000-0002-8454-9863)
- Nanxin Li (ORCID: https://orcid.org/0009-0006-4412-0997)
- Ashley Valentine
- Adriana Boateng-Kuffour
- Zahra Pakbaz
- Antony P. Martin (ORCID: https://orcid.org/0000-0003-4383-6038)
- Melanie Calvert (ORCID: https://orcid.org/0000-0002-1856-837X)
- Anthony Mason
- Farrukh Shah
Institutions
- NHS Blood and Transplant (GB)
- University of California, Irvine (US)
- Cellular Therapeutics (United Kingdom) (GB)
- NIHR Research Delivery Network (GB)
- NIHR Birmingham Biomedical Research Centre (GB)
- Vertex Pharmaceuticals (United States) (US)
- University of Birmingham (GB)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1007/s12325-024-03038-x
- Citations
- 2
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.88
Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Gilead Sciences
- Patient-Centered Outcomes Research Institute
- Vertex Pharmaceuticals
- Macmillan Cancer Support
- UK Research and Innovation
- Anthony Nolan
- National Institute for Health and Care Research
- Astellas Pharma
- European Regional Development Fund
- UCB Pharma
- Daiichi Sankyo Europe